(1254) A Survey of Community Pharmacists Participating in a 45-day Follow-up Call for Mental Health Medications

Objectives: From July 2022 to July 2023, a pilot project was conducted consisting of pharmacist-led consultations on patient adherence to mental health medications within medically underserved communities. These consultations took place 5 days and 45 days after picking up the new antipsychotic, antianxiety, or antidepressant medications. This health-equity focused study was conducted in large-chain retail pharmacies where patients may be affected by language barriers, transportation issues, or lack of access to healthcare.

The objective of this study is to conduct a survey of those pharmacists who lead these follow-up calls in-order to collect their insights on consultation techniques, work-flow integration, challenges faced, perceived value and patient outcomes.

Methods: Survey participants will consist of pharmacists from approximately 50 pharmacies who participated in the 45-day consultation calls. This survey is expected to give insight into the qualitative aspects of the 45-day follow up call and capture the opinions of participating pharmacists. It will consist of a 10-question survey including a demographics section pertaining to prior experience, training, and linguistic skills; a Likert scale matrix regarding the perceived benefits and challenges relating to the follow-up calls; and open-ended questions to allow for further elaboration on benefits, challenges, and future directions. The Likert scale was set from 1 to 5 with 5 being the highest or most positive score. The survey will be anonymous, voluntary, and will be collected using SurveyMonkey. Survey participants will receive reminders to complete the survey after 14 days to improve response rates. The results will be examined through descriptive analysis. Results from Likert scale questions will be presented as mean and median, and results from open-ended questions will be categorized and examined for common themes. This survey will be IRB approved.

Results: Pending analysis

Conclusions: Pending results